Swedish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
papilledema/ödem
Länken sparas på Urklipp
Sida 1 från 27 resultat
Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edema
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
TECHNICAL FIELD
This invention relates to a method of treating eye disease. Specifically, this invention relates to a method of removing pathological fluid accumulation in subretinal and intra-retinal spaces, by administering P2Y receptor agonists such as certain dinucleotides to a subject in need
Treatment and prevention of retinal edema with dopaminergic antagonists
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND OF THE INVENTION
1. Field of the Invention:
This invention relates to pharmacological treatment and prevention of retinal edema and more particularly to treatment and prevention of cystoid macular edema by administration of dopaminergic antagonists.
2. Description of the Prior
Treatment and prevention of retinal edema with dopaminergic antagonists
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND OF THE INVENTION
1. Field of the Invention:
This invention relates to pharmacological treatment and prevention of retinal edema and more particularly to treatment and prevenion of cystoid macular edema by administration of dopaminergic antagonists.
2. Description of the Prior Art:
Retinal
Treatment and prevention of retinal edema with dopaminergic antagonists
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND OF THE INVENTION
1. Field of the Invention:
This invention relates to pharmacological treatment and prevention of retinal edema and more particularly to treatment and prevention of cystoid macular edema by administration of dopaminergic antagonists.
2. Description of the Prior
Treatment of retinal edema with brinzolamide
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
The present invention is directed to the use of brinzolamide to treat retinal edema.
BACKGROUND OF THE INVENTION
In 1977, Miller, et al., did studies with bullfrogs and found that the pigment epithelium actively secretes sodium and calcium into the retinal space and absorbs chlorine and perhaps
Use of interferon-.beta. or .gamma. to treat retinal edema
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
TECHNICAL FIELD
The present invention relates to a novel remedy or preventive which is useful for retinal edema, and particularly for cystoid macular edema.
BACKGROUND ART
Vision is the most important of the senses, and diseases affecting visual function, such as reduced vision or blindness are
Diagnostic method and system for detecting early age macular degeneration, maculopathies and cystoid macular edema post cataract surgery
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF THE INVENTION
This invention relates to a method and system for using a calibrated retinoscope and parallel light technique to estimate the reflection of melanin particles in the retina to detect macular degeneration prior to physical symptoms.
BACKGROUND OF THE INVENTION
In the Western
Diagnostic method and system for detecting early age-related macular degeneration, maculopathies and cystoid macular edema post cataract surgery
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF THE INVENTION
This invention relates to a method and system for using a calibrated retinoscope and parallel light technique to estimate the reflection of melanin particles in the retina to detect macular degeneration prior to physical symptoms.
BACKGROUND OF THE INVENTION
In the Western
Prevention and treatment for retinal ischemia and edema
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND OF THE INVENTION
Diabetes effects over 16 million Americans. The World Health Organization indicates that diabetes afflicts 120 million people worldwide, and estimates that this number will increase to 300 million by the year 2025. Diabetics are faced with numerous complications including
Prevention and treatment of retinal ischemia and edema
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND OF THE INVENTION
Diabetes affects over 16 million Americans. The World Health Organization indicates that diabetes afflicts 120 million people worldwide, and estimates that this number will increase to 300 million by the year 2025. Diabetics are faced with numerous complications including
RNAi-mediated inhibition of H1F1A for treatment of ocular angiogenesis
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF THE INVENTION
The present invention relates to the field of interfering RNA compositions for inhibition of expression of hypoxia-inducible factor-1.alpha. (HIF-1.alpha.), the protein encoded by HIF1A mRNA, in ocular angiogenesis, including those cellular changes resulting from the
Method of treating edematous retinal disorders
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
TECHNICAL FIELD
This invention relates to a method of treating edematous retinal disorders. Specifically, this invention relates to a method of removing pathological fluid accumulation in subretinal and intra-retinal spaces.
BACKGROUND OF THE INVENTION
The retinal pigment epithelium (RPE) lies in
P.sup.1-(2'-deoxycytidine 5'-)P.sup.4-(uridine 5'-)tetraphosphate, tetra-(alkali metal) salt, for treating cystic fibrosis
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
TECHNICAL FIELD
This invention relates to a method of treating edematous retinal disorders. Specifically, this invention relates to a method of removing pathological fluid accumulation in subretinal and intra-retinal spaces. This invention also relates to dinucleoside polyphosphate salts, such as a
Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
TECHNICAL FIELD
This invention relates to a method of treating edematous retinal disorders. Specifically, this invention relates to a method of removing pathological fluid accumulation in subretinal and intra-retinal spaces. This invention also relates to dinucleoside polyphosphate salts, such as a
Pharmaceutical formulation comprising P1-(2'-deoxycytidine 5'-)P4-(uridine 5'-) tetraphosphate
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
TECHNICAL FIELD
This invention relates to a method of treating edematous retinal disorders. Specifically, this invention relates to a method of removing pathological fluid accumulation in subretinal and intra-retinal spaces.
BACKGROUND OF THE INVENTION
The retinal pigment epithelium (RPE) lies in
Den mest kompletta databasen med medicinska örter som stöds av vetenskapen
- Fungerar på 55 språk
- Växtbaserade botemedel som stöds av vetenskap
- Örter igenkänning av bild
- Interaktiv GPS-karta - märka örter på plats (kommer snart)
- Läs vetenskapliga publikationer relaterade till din sökning
- Sök efter medicinska örter efter deras effekter
- Organisera dina intressen och håll dig uppdaterad med nyheterna, kliniska prövningar och patent
Skriv ett symptom eller en sjukdom och läs om örter som kan hjälpa, skriv en ört och se sjukdomar och symtom den används mot.
* All information baseras på publicerad vetenskaplig forskning
